A5043387441- Head and Neck Cancer Studies
- Head and Neck Surgical Oncology
- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Oral health in cancer treatment
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Ear and Head Tumors
- Esophageal and GI Pathology
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Advances in Oncology and Radiotherapy
- Oral and Maxillofacial Pathology
- Management of metastatic bone disease
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Gastric Cancer Management and Outcomes
- Oral Health Pathology and Treatment
- Radiation Dose and Imaging
- Dysphagia Assessment and Management
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiation Therapy and Dosimetry
Homi Bhabha National Institute
2018-2025
Tata Memorial Hospital
2016-2025
Advanced Centre for Treatment, Research and Education in Cancer
2014-2025
Radiation Oncology Associates
2018-2025
Tata Main Hospital
2022
European Organisation for Research and Treatment of Cancer
2021
Bhabha Hospital
2021
Memorial Hospital
2017
Malabar Cancer Centre
2017
Whether patients with early-stage oral cancers should be treated elective neck dissection at the time of primary surgery or therapeutic after nodal relapse has been a matter debate.In this prospective, randomized, controlled trial, we evaluated effect on survival node (ipsilateral surgery) versus (watchful waiting followed by for relapse) in lateralized stage T1 T2 squamous-cell carcinomas. Primary and secondary end points were overall disease-free survival, respectively.Between 2004 2014,...
Purpose Chemoradiation with cisplatin 100 mg/m 2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). Increasingly, low-dose once-a-week substituted because perceived lower toxicity convenience. However, there no level 1 evidence comparable efficacy to weeks. Patients Methods In this phase III randomized trial, we assessed noninferiority 30 a week compared weeks, both administered concurrently curative intent radiotherapy patients...
There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation. Docetaxel was assessed as radiosensitizer this situation.This randomized phase II/III study. Adult (age ≥ 18 years) LAHNSCC planned for chemoradiation an Eastern Cooperative Oncology Group performance status 0-2 who were randomly assigned 1:1 to either radiation alone or concurrent docetaxel...
Background Because the addition of nimotuzumab to chemoradiation in patients with locally advanced head and neck cancer improved outcomes a phase 2 study, authors conducted 3 study confirm these findings. Methods This open‐label, investigator‐initiated, 3, randomized trial was from 2012 2018. Adult who were fit for radical 1:1 receive either radiotherapy (66‐70 grays) concurrent weekly cisplatin (30 mg/m ) (CRT) or same schedule CRT (200 mg) (NCRT).The primary endpoint progression‐free...
Abstract Background Grade ≥2 acute xerostomia between 3D conformal radiotherapy (RT) and intensity‐modulated (IMRT) was evaluated in patients with head neck squamous cell carcinomas (HNSCCs) treated radically. Methods Between 2005 2007, 59 HNSCC (T1–3, N0–2b) were randomized to IMRT or 3D‐RT. On RT, weekly xerostomia, dysphagia, dermatitis, mucositis graded by Radiation Therapy Oncology Group (RTOG) toxicity criteria. Patients underwent examination under anesthesia, positron emission...
Abstract Purpose To compare long-term disease-related outcomes and late radiation morbidity between intensity-modulated therapy (IMRT) three-dimensional conformal radiotherapy (3D-CRT) in head neck squamous cell carcinoma (HNSCC) the setting of a prospective randomized controlled trial. Methods Previously untreated patients with early to moderately advanced non-metastatic oropharynx, larynx, or hypopharynx (T1-T3, N0-N2b, M0) planned for comprehensive irradiation primary site bilateral nodes...
The objective of this study was to explore the potential role and safety neoadjuvant chemotherapy (NACT) in tumor shrinkage resultant mandibular preservation oral cancers compared with conventional surgical treatment.This a single-center, randomized, phase II trial treatment-naive histologically confirmed squamous cell carcinoma cavity cT2-T4 N0/N+, M0 (American Joint Committee on Cancer, seventh edition) stage, necessitating resection mandible for paramandibular disease absence...
Over the last 2 decades, transnasal endoscopic surgery (TES) has become most frequently employed surgical technique to treat sinonasal malignancies. The rarity and heterogeneity of cancers have hampered large non-population-based analyses.All patients receiving TES-including treatment between 1995 2021 in 5 referral hospitals were included. A prognostic study was performed, multivariable models transformed into nomograms. Training validation sets based on results from 3 European non-European...
Abstract Background The dominant pattern of failure for squamous cell carcinoma head and neck remains loco-regional, although distant metastases are now being increasingly documented. Radical radiotherapy with concurrent chemotherapy is contemporary standard care in the non-surgical management these loco-regionally advanced cancers, based on large randomized controlled trials utilizing high-dose cisplatin (80–100 mg/m 2 ) cycled every three-weekly during definitive radiotherapy. Although...